Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07557134Phase 2Not Yet Recruiting

E-CEL UVEC Cell Injection Treatment of Perianal Fistulas

Role: lead

NCT06456073Phase 1Recruiting

E-CEL UVEC Treatment for Anal Fissures

Role: collaborator

NCT04057833Phase 1Enrolling By Invitation

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

Role: collaborator

NCT04190862Phase 1Recruiting

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Role: collaborator

NCT05181540Phase 3Terminated

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Role: lead

NCT03483324Phase 1Completed

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

Role: lead

NCT03925935Phase 1Completed

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Role: lead

All 7 trials loaded